Evidence map›Paper›PMID 41459692›Full record

ReviewMovement disorders : official journal of the Movement Disorder Society2026

The Race to Salvage Glucocerebrosidase: Understanding Small-Molecule Therapies for GBA1-Associated Parkinsonism.

Mark J Henderson, Tiffany C Chen, Logan M Glasstetter, Yu Chen, Juan J Marugan, Ellen Sidransky

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Movement disorders : official journal of the Movement Disorder Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mark J HendersonDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, USA.ORCID https://orcid.org/0000-0001-8590-7338
Tiffany C ChenMedical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA.
Logan M GlasstetterMedical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA.
Yu ChenMedical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0001-5438-7309
Juan J MaruganDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, USA.ORCID https://orcid.org/0000-0002-3951-7061
Ellen SidranskyMedical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA.ORCID https://orcid.org/0000-0002-3019-8500

Funding

NCATS NIH HHSNHGRI NIH HHS
6 · The paper itself

Abstract

Variants in GBA1, the gene encoding the lysosomal enzyme glucocerebrosidase, cause Gaucher disease and confer an increased risk for parkinsonism. Strategies using small molecules can improve the function of glucocerebrosidase in lysosomes. A clear understanding of the mechanism-of-action of these compounds will facilitate development of GBA1-modulating drugs for Parkinson's disease.

Indexed as

Gaucher DiseaseGlucosylceramidaseParkinsonian DisordersAnimalsHumansGBA protein, humanGlucosylceramidaseactivatorschaperonesGaucher diseaseGBA1glucocerebrosidaseParkinson's disease

Identifiers

PMID41459692
PMCPMC13022582

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.